United Therapeutics Corp (UTHR) Com Stk USD0.01

Sell:$547.08Buy:$547.17Price decreased$8.97 (1.61%)

NASDAQ:Price increased1.12%
Market closed |
Prices delayed by at least 15 minutes
Sell:$547.08
Buy:$547.17
Change:Price decreased$8.97 (1.61%)
Deal now
Market closed |
Prices delayed by at least 15 minutes
Sell:$547.08
Buy:$547.17
Change:Price decreased$8.97 (1.61%)
Market closed |
Prices delayed by at least 15 minutes
Deal now

Company Information

About this company

United Therapeutics Corporation is a biotechnology company focused on the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening conditions. It markets and sells commercial products, including Tyvaso DPI (treprostinil) Inhalation Powder (Tyvaso DPI), Tyvaso (treprostinil) Inhalation Solution (Nebulized Tyvaso), Remodulin (treprostinil) Injection (Remodulin), Orenitram (treprostinil) Extended-Release Tablets (Orenitram), Unituxin (dinutuximab) Injection (Unituxin) and Adcirca (tadalafil) Tablets (Adcirca). Tyvaso DPI and Nebulized Tyvaso to treat pulmonary hypertension associated with interstitial lung disease (PH-ILD). Unituxin, an infused monoclonal antibody for the treatment of high-risk neuroblastoma and for the treatment of neuroblastoma after high-dose chemotherapy. Adcirca, an oral immediate-release tablet form of the PDE-5 inhibitor tadalafil. Its THY-100 is in preclinical development for congenital athymia.

Key people

Martine A. Rothblatt
Chairman of the Board, Chief Executive Officer
Michael Benkowitz
President and Chief Operating Officer
Christopher Patusky
Lead Independent Vice Chairman of the Board
James C. Edgemond
Chief Financial Officer and Treasurer
Paul A. Mahon
Executive Vice President, General Counsel, and Corporate Secretary
Christopher A. Causey
Independent Director
Richard A. Giltner
Independent Director
Raymond C. Kurzweil
Independent Director
Jan Malcolm
Independent Director
Click to see more

Key facts

  • Shares in issue
    77.42m
  • EPIC
    UTHR
  • ISIN
    US91307C1027
  • Location
    United States
  • Sector
    Healthcare
  • Industry
    Biotechnology & Drugs
  • Market cap
    $23.60bn
  • Employees
    1,400
  • Exchange
    NASDAQ
  • Index
    S&P 400 Mid Cap, TR Equity United States Index
  • Website
    Visit website

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.